Oruka Therapeutics, Inc. (NASDAQ: ORKA) is currently capturing the attention of investors with its impressive 71.70% potential upside. As a clinical-stage biopharmaceutical company, Oruka is at the forefront of developing novel monoclonal antibody therapeutics targeting psoriasis and other inflammatory and immunology (I&I) conditions.

With a market capitalization of $1.57 billion, Oruka Therapeutics is positioned in the dynamic biotechnology industry within the healthcare sector. Despite its status as a clinical-stage company, the stock’s current price sits at $32.42, with a 52-week range spanning from $6.78 to $35.53. This growth trajectory highlights impressive investor confidence and market interest, particularly in its…